Multiple gastrointestinal stromal tumors: analysis of clinicopathologic characteristics and prognosis of 20 patients

Figures & data

Table 1 Clinicopathologic findings of patients with multiple GISTs

Case	Age/sex	Tumor	Site/size (cm)/MF	Histotype	Risk category	Other diseases	Mutation status	Follow-up
Outcome	Months
1	37/F	1a 1b	Stomach/9/>5 Stomach/4/>5	S S	HR IR	Pulmonary chondromas	WT WT	NED	113
2	39/F	2a 2b 2c	Stomach /11/>5 Stomach/3.5/>5 Small intestine/too small/>5	M M M	HR IR IR	Adrenal adenoma Pulmonary chondromas	WT WT NA	NED	111
3	46/F	3a 3b	Duodenum/2.0/<5 Stomach/0.5/<5	S S	VLR VLR	Absent	NA NA	NED	122
4	51/M	4a 4b	Stomach/4.0/<5 Stomach/1.0/<5	S S	LR VLR	Absent	KIT exon11: c.1728_1739dup NA	NED	57
5	51/F	5a 5b	Small intestine/4.5/>10 Small intestine/0.5/>10	S S	HR HR	Breast cancer	WT WT	NED	183
6	52/M	6a 6b 6c	Small intestine/13/>5 Small intestine/4/>5 Small intestine/2/>5	S S S	HR HR IR	Absent	KIT exon11:c.1655_1666del WT NA	AWD	62
7	55/F	7a	Stomach/6.0/<5	S	IR	Neurofibromas	WT	NED	37
		7b	Small intestine/2/<5	S	VLR		NA
		7c	Small intestine/1/<5	S	VLR		NA
		7d	Small intestine/1/<5	S	VLR		NA
		7e	Small intestine/0.5/<5	S	VLR		NA
		7f	Small intestine/0.5/<5	S	VLR		NA
8	57/M	8a 8b 8c	Mesentery/17/>5 Mesentery/11/>5 Mesentery/2/>5	S S S	HR HR IR	Absent	KIT exon11: p.M552_Q556del NA NA	DOD	40
9	58/F	9a 9b	Stomach/2/<5 Stomach/0.9/<5	S S	LR VLR	Breast cancer	KIT exon11: Q556-E561 Del KIT exon11:Ins QPS+V560E	NED	3
10	59/F	10a 10b 10c	Rectum/3/>5 Rectum/1/>5 Rectum/too small/>5	S S S	HR IR IR	Absent	PDGFRA exon12: p.P567P WT WT	NED	158
11	64/F	11a 11b 11c 11d 11e 11f	Small intestine/6/<5 Small intestine/4.5/<5 Small intestine/2/<5 Small intestine/2/<5 Small intestine/2/<5 Small intestine/1.8/<5	S S S S S S	HR LR VLR VLR VLR VLR	Neurofibromas	PDGFRA exon18:p.V824V PDGFRA exon18:p.V824V PDGFRA exon18:p.V824V PDGFRA exon18:p.V824V PDGFRA exon18:p.V824V NA	NED	125
12	66/M	12a 12b	Stomach/3/<5 Stomach/0.4/<5	S S	LR VLR	Absent	WT NA	NED	65
13	68/M	13a 13b 13c	Small intestine/9/<5 Small intestine/3.8/<5 Small intestine/1.9/<5	S S S	HR LR VLR	Absent	NA NA NA	DOPC	/
14	69/M	14a 14b	Stomach/2.9/<5 Stomach/1.5/<5	S S	LR VLR	Absent	PDGFRA exon 18 : p.V824V KIT exon11: p.Y578_D579dup	DUNC	47
15	72/M	15a 15b	Stomach/5/<5 Stomach/1/<5	M M	LR VLR	Absent	PDGFRA exon 12: p.P567P NA	DOD	24
16	73/F	16a 16b	Stomach/3.5/>10 Stomach/2.5/>10	M M	HR HR	Absent	KIT exon11: p.T574_R588dup PDGFRA exon18: p.D842V	DUNC	52
17	74/F	17a 17b	Stomach/1.6/<5 Stomach/0.3/<5	S S	LR VLR	Absent	NA NA	NED	100
18	76/F	18a 18b 18c	Stomach/8/>5 Stomach/2/>5 Stomach/too small/>5	S S S	HR IR IR	Absent	KIT exon11: p.V559_T574del WT WT	NED	142
19	79/M	19a	Small intestine/6.5/>5	S	HR	Absent	KIT exon11: p.Y570_L576del	DOD	118
	19b	Small intestine/1.2/>5	S	IR		KIT exon11: p.Y570_L576del
20	80/M	20a 20b	Stomach/3.5/<5 Stomach/1.5/<5	E S	IR VLR	Absent	KIT exon11: p.W557R PDGFRA exon18: p.D842V	NED	66

Abbreviations: AWD, alive with disease; NED, no evidence of disease; DOD, dead of disease; DOPC, dead of postoperative complications; DUNC, dead of unknown causes; E, epithelioid; S, spindle; MF, mitotic figures, (50/HPF); VLR, very low risk; LR, low risk; IR, intermediate risk; HR, high risk; WT, wild-type; NA, not available.

Figure 1 Progression-free survival (A) and overall survival (B) for patients with multiple GISTs.